FIELD: pharmacology.
SUBSTANCE: invention relates to RTN prodrugs, pharmaceutical compositions containing such RTN prodrugs, and their use for the treatment of hypoparathyroidism.
EFFECT: effective treatment of hypoparathyroidism.
22 cl, 34 ex
Title | Year | Author | Number |
---|---|---|---|
LIQUID PHARMACEUTICAL FORMULATIONS OF PTH CONJUGATES | 2020 |
|
RU2817015C2 |
METHOD OF TREATING OR CONTROL OF HYPOPARATHYROIDUS USING PARATHROOID HORMONE (PTH) CONJUGATE | 2019 |
|
RU2806753C2 |
DOSAGE MODE OF PTH COMPOUND OF CONTROLLED RELEASE | 2017 |
|
RU2777357C2 |
CONTROLLED RELEASE COMBINATION THERAPY WITH CNP AGONISTS | 2017 |
|
RU2768747C2 |
PTH COMPOUNDS WITH LOW PEAK-TO-MINIMUM RATIOS | 2017 |
|
RU2766959C2 |
NOVEL POLYMER hGH PRODRUGS | 2015 |
|
RU2718664C2 |
IL-2 CONJUGATES | 2019 |
|
RU2809259C2 |
STABLE LOCAL DRUG LEVELS FOR INNATE IMMUNITY AGONISTS | 2020 |
|
RU2817710C2 |
BENZAZEPINE COMPOUNDS, CONJUGATES AND THEIR USE | 2018 |
|
RU2780334C2 |
COMPOSITIONS AND METHODS RELATING TO DRUG CONJUGATES WITH ANTI-CD19 ANTIBODIES | 2019 |
|
RU2806333C2 |
Authors
Dates
2021-05-04—Published
2017-02-28—Filed